FibroBiologics (NASDAQ:FBLG) Receives “Buy” Rating from D. Boral Capital

FibroBiologics (NASDAQ:FBLG)‘s stock had its “buy” rating reaffirmed by equities researchers at D. Boral Capital in a research report issued to clients and investors on Thursday,Benzinga reports. They currently have a $16.00 price target on the stock.

Several other equities research analysts have also recently weighed in on FBLG. HC Wainwright reissued a “buy” rating and issued a $12.00 price objective on shares of FibroBiologics in a research report on Thursday. Rodman & Renshaw began coverage on FibroBiologics in a research note on Thursday, December 12th. They set a “buy” rating and a $12.00 price objective for the company. Four equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, FibroBiologics presently has a consensus rating of “Buy” and an average target price of $13.00.

FibroBiologics Stock Performance

NASDAQ:FBLG opened at $1.23 on Thursday. The stock’s 50 day moving average price is $1.95 and its 200 day moving average price is $2.48. FibroBiologics has a 52 week low of $1.06 and a 52 week high of $15.50.

Institutional Trading of FibroBiologics

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. The Manufacturers Life Insurance Company bought a new position in FibroBiologics during the third quarter worth about $32,000. Jane Street Group LLC acquired a new stake in FibroBiologics in the 3rd quarter valued at approximately $37,000. Intech Investment Management LLC acquired a new stake in FibroBiologics in the 4th quarter valued at approximately $25,000. Virtu Financial LLC acquired a new stake in FibroBiologics in the 4th quarter valued at approximately $30,000. Finally, Raymond James Financial Inc. acquired a new position in shares of FibroBiologics during the 4th quarter worth approximately $37,000.

About FibroBiologics

FibroBiologics, Inc operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. It holds 150+ U.S. and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer.